B-Cure Laser

Company Overview

Snapshot

Founded in October 2007, B-Cure Laser operates with 11–50 employees, developing low-level laser therapy devices. The company went public on TASE in May 2021, raising $25.5 million.

Business overview

B-Cure Laser develops and markets portable, rechargeable, and user-friendly medical devices that provide clinical low-level laser power. These devices are designed for the rapid, noninvasive, and efficient treatment of various conditions, including pain, orthopedic issues, wounds, burns, skin problems, inflammation, and sports injuries. The company's products utilize class-one lasers and are sold over the counter, serving markets in Health Tech & Life Sciences, specifically within Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In March 2024, news emerged regarding the chairman's compensation request of nearly one million shekels for a part-time position, following a 96% collapse in the company's stock. This signals significant internal governance challenges and raises concerns about executive compensation in the context of declining company performance, indicating potential instability for investors.

Company Intelligence Q&A

When did B-Cure Laser go public?

B-Cure Laser went public on TASE in May 2021.

What was the capital raised during B-Cure Laser's public offering?

B-Cure Laser raised $25.5 million during its public offering in May 2021.

What was the reported stock performance in March 2024?

In March 2024, B-Cure Laser's stock was reported to have collapsed by 96%.

What regulatory scrutiny did B-Cure Laser face in February 2024?

In February 2024, the Securities Authority initiated an examination into Erika B-Cure Laser regarding European approvals.

What was the leadership change at B-Cure Laser in December 2022?

In December 2022, B-Cure Laser dismissed its CEO after six months, citing a 'crisis of confidence'.